QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

GSK

QT69GSK plc
NYSE·Healthcare·Drug Manufacturers - General·UK
Latest market price
50.67
-1.48-2.84%
OverviewShort InterestFilings
GSKQT69GSK plc·NYSE
OverviewShort InterestFilings
50.67-2.84%
TA
Loading chart...
Screen all →
LLY-1.21%$1098.57JNJ-2.48%$228.39ABBV-2.08%$216.63NVS-2.52%$147.08MRK-1.36%$113.87AZN-1.66%$174.93NVO-0.76%$43.19AMGN-1.19%$337.60
Snapshot
Index-P/E13.54EPS (ttm)
4.51
Insider Own-
Shs Outstand4.05B
Perf Week-4.14%
Market Cap103.94BForward P/E9.67EPS next Y5.24Insider Trans-Shs Float-Perf Month-0.74%
Enterprise Value124.58BPEG0.15EPS next Q1.68Inst Own-Short Float-Perf Quarter-3.25%
Income7.68BP/S2.40EPS this Y6.10%Inst Trans-Short Ratio-Perf Half Y3.87%
Sales43.34BP/B4.42EPS next Y9.55%ROA9.27%Short Interest-Perf YTD3.32%
Book/sh7.51P/C10.45EPS next 5Y5.44%ROE35.78%52W High61.70 -17.88%Perf Year27.57%
Cash/sh1.48P/FCF15.66EPS past 3/5Y-ROIC13.76%52W Low35.45 42.93%Perf 3Y-
Dividend Est.1.80 (3.56%)EV/EBITDA8.15Sales past 3/5Y6.07% 6.66%Gross Margin72.74%Volatility1.22% 1.32%Perf 5Y-
Dividend TTM1.80 (3.56%)EV/Sales2.87EPS Y/Y TTM174.98%Oper. Margin22.34%ATR (14)1.04Perf 10Y-
Dividend Ex-DateMay 15, 2026Quick Ratio0.52Sales Y/Y TTM9.57%Profit Margin17.78%RSI (14)44.26Recom2.83
Dividend Gr. 3/5Y0.34% -3.77%Current Ratio0.79EPS Q/Q9.73%SMA20-1.11%Beta0.33Target Price53.00
Payout44.52%Debt/Eq1.07Sales Q/Q8.55%SMA50-3.79%Rel Volume1.06Prev Close52.15
Employees68,629LT Debt/Eq0.92EarningsJul 28SMA2001.18%Avg Volume3.97MPrice50.67
IPO DateMar 28, 1980Option/ShortYes / YesEPS/Sales Surpr.6.90% 0.68%Net Debt/EBITDA1.35Volume4,218,170Change-2.84%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-06-26DowngradeBarclaysEqual Weight → Underweight
Oct-30-25ReiteratedCFRA$53
Apr-15-25InitiatedBNP Paribas ExaneNeutral$35
Nov-12-24DowngradeJefferiesBuy → Hold
Oct-31-24DowngradeGuggenheimBuy → Neutral
Jul-08-24DowngradeUBSBuy → Neutral
Jul-02-24ReiteratedJefferiesBuy$53
Apr-11-24ReiteratedGuggenheimBuy$36
Apr-11-24ReiteratedMorgan StanleyUnderweight$85
Mar-04-24UpgradeGuggenheimNeutral → Buy
Latest News
Jun-18-26
Jun-18-2603:41PM
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems BewilderingSeekingAlpha
Jun-17-26
Jun-17-2601:29PM
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsBenzinga
11:24AM
GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract InfectionsBenzinga
Jun-16-26
Jun-16-2612:22PM
GSK's Exdensur Receives Canada Approval To Treat Severe Asthma, Chronic Rhinosinusitis With Nasal PolypsBenzinga
Jun-12-26
Jun-12-2607:30AM
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend YieldsBenzinga
05:09AM
GSK's Momelotinib Receives Orphan Drug Designation From FDA And European Medicines Agency For VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) SyndromeBenzinga
Jun-11-26
Jun-11-2603:43PM
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase InhibitorsSeekingAlpha
Jun-10-26
Jun-10-2603:52PM
GSK plc (GSK) M&A Call TranscriptSeekingAlpha
03:52PM
GSK plc (GSK) M&A Call TranscriptSeekingAlpha
Jun-09-26
Jun-09-2603:03PM
GSK plc (GSK) Nuvalent, Inc. - M&A Call - SlideshowSeekingAlpha
03:03PM
GSK plc (GSK) Nuvalent, Inc. - M&A Call - SlideshowSeekingAlpha
01:26PM
Nasdaq 100 Tumbles Over 3%, Marvell Crashes 12%: Stock Market TodayBenzinga
01:26PM
Nasdaq 100 Tumbles Over 3%, Marvell Crashes 12%: Stock Market TodayBenzinga
06:52AM
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer NuvalentBenzinga
06:52AM
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer NuvalentBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue43,92843,12540,093
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A11,99511,90411,562
Gross Profit31,93231,22128,531
Selling, General and Administrative Excl. Other12,24211,99714,075
Research and Development10,3859,9348,179
Other Operating Expense-1,985-1,7171,139
Operating Income11,28911,0075,138
Interest Expense927907840
Unusual Expense
———
Non-Operating Income (Expense)380330-123
Net Income Before Taxes9,9839,7704,443
Income Taxes1,4511,468672
Consolidated Net Income7,8277,5463,290
Net Income From Continuing Operations8,5328,3023,771
Net Income7,8277,5463,290
EPS (Recurring)4.597.451.61
EPS (Basic, Before Extraordinaries)4.597.451.61
EPS (Diluted)4.517.341.58
EBITDA15,11713,7328,521
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio11.246.68—
Price To Sales Ratio2.321.15—
Gross Margin72.6972.4071.16
Operating Margin25.7025.5212.82
Net Margin17.8217.508.21
Shares Outstanding2,0121,0132,039
Market Capitalization101,94849,678—
Operating Lease Expense
———
Insider Trading Volume
$53.31$48.28$43.25$38.21$33.18● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR